Hyperimmune immunoglobulin for people with COVID‐19
V Piechotta, C Iannizzi, I Monsef… - Cochrane Database …, 2023 - cochranelibrary.com
Background Hyperimmune immunoglobulin (hIVIG) contains polyclonal antibodies, which
can be prepared from large amounts of pooled convalescent plasma or prepared from …
can be prepared from large amounts of pooled convalescent plasma or prepared from …
COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes
D Focosi, M Franchini, L Pirofski… - Clinical microbiology …, 2022 - Am Soc Microbiol
Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …
available as soon as there are survivors. The COVID-19 pandemic represented the first …
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study
Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective …
syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective …
Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine
C Keech, G Albert, I Cho, A Robertson… - New england journal …, 2020 - Mass Medical Soc
Background NVX-CoV2373 is a recombinant severe acute respiratory syndrome
coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS …
coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS …
Convalescent plasma antibody levels and the risk of death from Covid-19
Background Convalescent plasma has been widely used to treat coronavirus disease 2019
(Covid-19) under the presumption that such plasma contains potentially therapeutic …
(Covid-19) under the presumption that such plasma contains potentially therapeutic …
Convalescent plasma for COVID-19. A randomized clinical trial
A Gharbharan, CCE Jordans, C Geurtsvankessel… - MEDRxiv, 2020 - medrxiv.org
Structured abstract for full paper Background After recovery from COVID-19, most patients
have anti-SARS-CoV-2 neutralizing antibodies. Their convalescent plasma could be an …
have anti-SARS-CoV-2 neutralizing antibodies. Their convalescent plasma could be an …
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
A Gharbharan, CCE Jordans… - Nature …, 2021 - nature.com
In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS …
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS …
[HTML][HTML] The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated
patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose …
patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose …
Convalescent plasma therapy for COVID-19: state of the art
Convalescent plasma (CP) therapy has been used since the early 1900s to treat emerging
infectious diseases; its efficacy was later associated with the evidence that polyclonal …
infectious diseases; its efficacy was later associated with the evidence that polyclonal …
Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina
DS Ojeda, MM Gonzalez Lopez Ledesma… - PLoS …, 2021 - journals.plos.org
We report the emergency development and application of a robust serologic test to evaluate
acute and convalescent antibody responses to SARS-CoV-2 in Argentina. The assays …
acute and convalescent antibody responses to SARS-CoV-2 in Argentina. The assays …